Urinary angiostatin levels are elevated in patients with epithelial ovarian cancer

Gynecologic Oncology

Volumn 117, Issue 1, 2010, Pages 117-124

  Drenberg, Christina D ^a   Saunders, Beatriz O ^a   Wilbanks, George D ^a   Chen, Ren ^b   Nicosia, Roberto F ^d,e   Kruk, Patricia A ^a,b,c   Nicosia, Santo V ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Angiostatin; CA125; Epithelial ovarian cancer biomarker; Hepatocyte growth factor; Urine; Vascular endothelial growth factor

Indexed keywords

ANGIOSTATIN; CA 125 ANTIGEN; CREATININE; ENDOSTATIN; SCATTER FACTOR; TUMOR MARKER; VASCULOTROPIN;

ADULT; ARTICLE; ASCITES; CANCER GRADING; CANCER SIZE; CANCER STAGING; CANCER SURGERY; COHORT ANALYSIS; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIAL OVARIAN CANCER; FEMALE; GYNECOLOGIC DISEASE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; OVARY CANCER; PERITONEUM CANCER; PILOT STUDY; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; URINE LEVEL;

ADULT; ANGIOSTATINS; CASE-CONTROL STUDIES; COHORT STUDIES; ENDOSTATINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIAL CELLS; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77949310956     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.12.011     Document Type: Article

References (33)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J. Clin. 58 (2008) 71-96
2. Bast Jr. R.C., Badgwell D., Lu Z., Marquez R., Rosen D., Liu J., et al. New tumor markers: CA125 and beyond. Int. J. Gynecol. Cancer 15 Suppl. 3 (2005) 274-281
3. Bast Jr. R.C., Brewer M., Zou C., Hernandez M.A., Daley M., Ozols R., et al. Prevention and early detection of ovarian cancer: mission impossible?. Recent Results Cancer Res. 174 (2007) 91-100
4. Moore R.G., Brown A.K., Miller M.C., Skates S., Allard W.J., Verch T., et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol. Oncol. 108 (2008) 402-408
5. Rosen D.G., Wang L., Atkinson J.N., Yu Y., Lu K.H., Diamandis E.P., et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol. Oncol. 99 (2005) 267-277
6. Zhang Z., Yu Y., Xu F., Berchuck A., van Haaften-Day C., Havrilesky L.J., et al. Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol. Oncol. 107 (2007) 526-531
7. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 25 (2004) 581-611
8. Nicosia S.V., Ku Ni Ni K., Oliveros-Saunders B., Giacomini G., Pierro E., Mayer J., et al. Ovarian mesothelium (surface epithelium) in normal, pathological and experimental conditions. In: Motta P.M. (Ed). Recent advances in microscopy of cells, tissues, and organs (1997), Antonio Delfino Editore, Rome 509-517
9. Holash J., Wiegand S.J., and Yancopoulos G.D. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 18 (1999) 5356-5362
10. Rubatt J.M., Darcy K.M., Hutson A., Bean S.M., Havrilesky L.J., Grace L.A., et al. Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: a Gynecologic Oncology Group study. Gynecol. Oncol. 112 (2009) 469-474
11. Hazelton D., Nicosia R.F., and Nicosia S.V. Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy. Clin. Cancer Res. 5 (1999) 823-829
12. Alvarez Secord A., Sayer R., Snyder S.A., Broadwater G., Rodriguez G.C., Berchuck A., et al. The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer. Gynecol. Oncol. 94 (2004) 74-79
13. Fuhrmann-Benzakein E., Ma M.N., Rubbia-Brandt L., Mentha G., Ruefenacht D., Sappino A.P., et al. Elevated levels of angiogenic cytokines in the plasma of cancer patients. Int. J. Cancer 85 (2000) 40-45
14. Nguyen M., Watanabe H., Budson A.E., Richie J.P., Hayes D.F., and Folkman J. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J. Natl. Cancer Inst. 86 (1994) 356-361
15. Sowter H.M., Corps A.N., and Smith S.K. Hepatocyte growth factor (HGF) in ovarian epithelial tumour fluids stimulates the migration of ovarian carcinoma cells. Int. J. Cancer 83 (1999) 476-480
16. Jandu N., Richardson M., Singh G., Hirte H., and Hatton M.W. Human ovarian cancer ascites fluid contains a mixture of incompletely degraded soluble products of fibrin that collectively possess an antiangiogenic property. Int. J. Gynecol. Cancer 16 (2006) 1536-1544
17. Murthi P., Barker G., Nowell C.J., Rice G.E., Baker M.S., Kalionis B., et al. Plasminogen fragmentation and increased production of extracellular matrix-degrading proteinases are associated with serous epithelial ovarian cancer progression. Gynecol. Oncol. 92 (2004) 80-88
18. Nathan F.E., Hernandez E., Dunton C.J., Treat J., Switalska H.I., Joseph R.R., et al. Plasma thrombospondin levels in patients with gynecologic malignancies. Cancer 73 (1994) 2853-2858
19. Yabushita H., Noguchi M., Obayashi Y., Kishida T., Noguchi Y., Sawaguchi K., et al. Angiostatin expression in ovarian cancer. Oncol. Rep. 10 (2003) 1225-1230
20. Yokoyama Y., Sedgewick G., and Ramakrishnan S. Endostatin binding to ovarian cancer cells inhibits peritoneal attachment and dissemination. Cancer Res. 67 (2007) 10813-10822
21. Cao Y., Veitonmaki N., Keough K., Cheng H., Lee L.S., and Zurakowski D. Elevated levels of urine angiostatin and plasminogen/plasmin in cancer patients. Int. J. Mol. Med. 5 (2000) 547-551
22. Linder-Stragliotto C., Strander H., Munck-Wikland E., and Sten-Linder M. Low levels of endostatin in the urine from patients with malignant disease. Tumour Biol. 23 (2002) 222-227
23. Sten-Linder M., Linder C., Strander H., Munck-Wikland E., Wersall P., Linder S., et al. Angiostatin fragments in urine from patients with malignant disease. Anticancer Res. 19 (1999) 3409-3414
24. Anderson N.S., Bermudez Y., Badgwell D., Chen R., Nicosia S.V., Bast Jr. R.C., et al. Urinary levels of Bcl-2 are elevated in ovarian cancer patients. Gynecol. Oncol. 112 (2009) 60-67
25. Lu K.H., Patterson A.P., Wang L., Marquez R.T., Atkinson E.N., Baggerly K.A., et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin. Cancer Res. 10 (2004) 3291-3300
26. Nicosia S.V., Wilbanks G.D., Saunders B., Mayer J., Cardosi R.J., Kruk P.A., et al. Cytology of human ovarian surface epithelial brushings. Cancer 102 (2004) 1-10
27. Folkman J. Fighting cancer by attacking its blood supply. Sci. Am. 275 (1996) 150-154
28. Zhou H.Y., Pon Y.L., and Wong A.S. HGF/MET signaling in ovarian cancer. Curr. Mol. Med. 8 (2008) 469-480
29. Hata K., Dhar D.K., Kanasaki H., Nakayama K., Fujiwaki R., Katabuchi H., et al. Serum endostatin levels in patients with epithelial ovarian cancer. Anticancer Res. 23 (2003) 1907-1912
30. Perri S.R., Martineau D., Francois M., Lejeune L., Bisson L., Durocher Y., et al. Plasminogen Kringle 5 blocks tumor progression by antiangiogenic and proinflammatory pathways. Mol. Cancer Ther. 6 (2007) 441-449
31. Yokoyama Y., Dhanabal M., Griffioen A.W., Sukhatme V.P., and Ramakrishnan S. Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Res. 60 (2000) 2190-2196
32. Persano L., Crescenzi M., and Indraccolo S. Anti-angiogenic gene therapy of cancer: current status and future prospects. Mol. Aspects Med. 28 (2007) 87-114
33. Lawrence H.P. Salivary markers of systemic disease: noninvasive diagnosis of disease and monitoring of general health. J. Can. Dent. Assoc. 68 (2002) 170-174